ROS1 and non-small cell lung carcinoma: In an additional study, nivolumab was assessed with carboplatin, paclitaxel, and bevacizumab in NSCLC patients with stage IIIB/IV or recurrent NSCLC without sensitizing EGFR, ALK, or ROS1 alterations [25].